Potential impact of AUSFTA  on Australia's blood supply

Frenzel, Wolfgang

doi:10.5694/j.1326-5377.2007.tb00983.x

Topics

In reply: I would like to respond to the letter by Kennedy et al regarding the passive transfer of human T-lymphotropic virus (HTLV) antibodies following Octagam (intravenous immunoglobulin [IVIg]) administration.

Octapharma, Vienna, Austria

Correspondence: wolfgang.frenzel@octapharma.at

Competing interests:

Octapharma is the manufacturer of Octagam. I am employed by Octapharma in the role of International Medical Director.

1. Australian Government Department of Health and Ageing. Therapeutic Goods Administration. Standards for blood components. Therapeutic Goods Order No. 74. 2006. http://www.tga.gov.au/docs/html/tgo/tgo74.htm (accessed Mar 2007).
2. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 11th ed. January 2005. Strasbourg: Council of Europe Publishing, 2005.
3. US Food and Drug Administration. Code of Federal Regulations, Title 21, Part 610, Subpart E. Testing requirements for communicable disease agents (4-1-04 edition). Rockville, Md: FDA, 2004.

Online responses are no longer available. Please refer to our instructions for authors page for more information.